Interestingly, BEI exhibited a promising glutathione S-transferase isozymes inhibition. The results of this study suggest that BEI seems to be a promising molecule to be used in design of new anticancer agents that provide superiority to present commercial anticancer drugs. The results of this study suggest that BEI seems to be a promising molecule to be used in design of new anticancer agents that provide superiority to present commercial anticancer drugs. Silver nanoparticles (AgNPs) are one of the most investigated nanostructures in recent years, which gives more challenging and promising qualities in different biomedical applications. The AgNPs synthesized by the green approach provide potential healthcare benefits over chemical approaches, including improvement of tissue restoration, drug delivery, diagnosis, environmentally friendly and a boon to cancer treatment. In the current scenario, the development of safe and effective drug delivery systems is the utmost concern of formulation development scientists as well as clinicians. Google, Web of Science, PubMed, portals have been searched for potentially relevant literature to get latest developments and updated information related to different aspects of green synthesized AgNPs along with their biomedical applications especially in the treatment of different types of cancers. The present review highlights the latest published research regarding the different green approaches for the synthesis of AgN The search for novel metallic chemical compounds with toxicogenic effects have been of great importance for more efficient cancer treatment. The study evaluated the cytotoxic, genotoxic and mutagenic activity of organoteluran RF07 in S-180 cell line. The bioassays used were cell viability with 3-(4,5-dimethyl-2-thiazole)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) test, evaluation of apoptosis and necrosis using fluorescence and flow cytometry, cytokinesis-block micronucleus test and comet assay. The compound was tested at 1; 2.5 and 5 µM. The results showed the cytotoxicity of RF07 at concentrations of 2.5, 5, 10 and 20 µM when compared to the negative control. For genotoxicity tests, RF07 showed effects in all concentrations assessed by increased index and frequencies of damage and mutagenic alterations. The compound was also cytotoxic due to the significant decrease in nuclear division index, with significant values of apoptosis and necrosis. The results of fluorescence and flow cytometry showed apoptosis as the main type of cell death caused by RF07 at 5 µM, which is thought to avoid an aggressive immune response of the organism. In addition to cytotoxic and genotoxic effects, RF07 creates good perspectives for future antitumor formulations. In addition to cytotoxic and genotoxic effects, RF07 creates good perspectives for future antitumor formulations. HSP70 is a survival factor for tumor cells in transformation and in tumor progression as well as in anti-apoptotic response. Several inhibitors targeting HSP70 ATPase function displayed off-target affect but PES which targets HSP70 substrate binding domain prevents tumor cell survival prominently. However, PES may not bind HSP70 in the absence of nucleotide. This research aimed to design a unique inhibitor molecule that work both in the presence and absence of nucleotides to amplify inhibition. A set of chimeric coumarine-pyrazole derivatives determined by in silico techniques and synthesized to elucidate their inhibitory effects. Cell viability experiments displayed KBR1307 as the most efficient inhibitor. A set of characterization experiments performed, and results compared to that of PES agent. https://www.selleckchem.com/products/10-dab-10-deacetylbaccatin.html Binding constant, ATP hydrolysis rate, and percent aggregation determined in the presence and absence of inhibitors. In silico docking experiments showed that only KBR1307 bind HSP70 substrate binding domain and interact with cochaperone interface. Binding experiments indicated that KBR1307 bind HSP70 both in the presence and absence of nucleotides but PES not. Both inhibitors significantly lower HSP70 ATPase activity and substrate protein disaggregation activity. However, KBR1307 display lower IC50 value at MCF-7 cell line compared to PES. Both inhibitors do not alter HSP70 secondary structure composition and overall stability. KBR1307 effectively inhibits HSP70 compared to PES and provides promising template for novel anticancer drug development. KBR1307 effectively inhibits HSP70 compared to PES and provides promising template for novel anticancer drug development.With the emergence of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the whole world is suffering from atypical pneumonia, which resulted in more than 559,047 deaths worldwide. In this time of crisis and urgency, the only hope comes from new candidate vaccines and potential antivirals. However, formulating new vaccines and synthesizing new antivirals are a laborious task. Therefore, considering the high infection rate and mortality due to COVID-19, utilization of previous information, and repurposing of existing drugs against valid viral targets have emerged as a novel drug discovery approach in this challenging time. The transmembrane spike (S) glycoprotein of coronaviruses (CoVs), which facilitates the virus's entry into the host cells, exists in a homotrimeric form and is covered with N-linked glycans. S glycoprotein is known as the main target of antibodies having neutralizing potency and is also considered as an attractive target for therapeutic or vaccine development. Similarly, targeting of N-linked glycans of S glycoprotein envelope of CoV via carbohydrate-binding agents (CBAs) could serve as an attractive therapeutic approach for developing novel antivirals. CBAs from natural sources like lectins from plants, marine algae and prokaryotes and lectin mimics like Pradimicin-A (PRM-A) have shown antiviral activities against CoV and other enveloped viruses. However, the potential use of CBAs specifically lectins was limited due to unfavorable responses like immunogenicity, mitogenicity, hemagglutination, inflammatory activity, cellular toxicity, etc. Here, we reviewed the current scenario of CBAs as antivirals against CoVs, presented strategies to improve the efficacy of CBAs against CoVs; and studied the molecular interactions between CBAs (lectins and PRM-A) with Man9 by molecular docking for potential repurposing against CoVs in general, and SARSCoV- 2, in particular.